Steroid-Free hope? early trial of ruxolitinib for young GVHD patients ends prematurely
NCT ID NCT06695507
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested whether the drug ruxolitinib could be used as the first treatment for chronic graft-versus-host disease (cGVHD) in children and young adults, instead of the usual high-dose steroids. The goal was to see if it could control the disease while avoiding steroid side effects. However, the study was terminated early and only enrolled one participant, so no meaningful conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ruxolitinib
What this could lead to
If successful, this approach could reduce the need for high-dose steroids in young patients with chronic GVHD, potentially lowering side effects while still controlling the disease.
What could go wrong
This was a very small, early-phase pilot study that was terminated after enrolling only 1 participant. The results are not generalizable, and the effectiveness of upfront ruxolitinib remains unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States